Investment Thesis
4D Molecular Therapeutics is a pre-revenue biotech company with severe operational losses consuming ~$109M in annual operating cash flow against only $85.2M in revenue, indicating the revenue is insufficient to cover core operations. The company is burning cash rapidly with negative free cash flow of -$109.6M annually, which will deplete the current $60.2M cash position within months without significant changes. While the balance sheet shows reasonable equity backing, the fundamental business model is unsustainable at current burn rates without substantial revenue growth or capital raises.
Strengths
- Strong balance sheet with $505.7M stockholders equity and minimal debt ($0 long-term debt)
- Excellent liquidity position with 9.39x current and quick ratios indicating short-term solvency
- Diversified asset base of $566.7M providing runway for operations
Risks
- Severe cash burn of $109.6M annually with only $60.2M cash available; runway exhausted in ~6-7 months
- Operating losses of $159.5M with negative operating margin of -187.2% indicating revenue cannot cover core costs
- Revenue base of $85.2M insufficient to support current operational expense structure; company heavily dependent on R&D spending without commercial validation
Key Metrics to Watch
- Operating cash flow trend and path to breakeven cash burn
- Revenue growth rate and pipeline advancement toward commercialization milestones
- Cash runway depletion rate and necessity for capital raises or major cost restructuring
Financial Metrics
Revenue
85.2M
Net Income
-140.1M
EPS (Diluted)
$-2.42
Free Cash Flow
-109.6M
Total Assets
566.7M
Cash
60.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-187.2%
Net Margin
-164.4%
ROE
-27.7%
ROA
-24.7%
FCF Margin
-128.6%
Balance Sheet & Liquidity
Current Ratio
9.39x
Quick Ratio
9.39x
Debt/Equity
0.00x
Debt/Assets
10.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T20:00:12.612150 |
Data as of: 2025-12-31 |
Powered by Claude AI